Insiders Sarepta Therapeutics, Inc.

Equities

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-25 EDT			5-day change	1st Jan Change
158.1 ^USD	-3.53%		+34.50%	+63.91%

06-24	Morgan Stanley Adjusts Sarepta Therapeutics' Price Target to $200 From $165, Keeps Overweight Rating	MT
06-24	Evercore ISI Raises Price Target on Sarepta Therapeutics to $185 From $139, Maintains In Line Rating	MT

Sarepta Therapeutics Insider Sold Shares Worth $1,848,795, According to a Recent SEC Filing	03-12	MT
Sarepta Therapeutics Insider Sold Shares Worth $385,480, According to a Recent SEC Filing	03-07	MT
Sarepta Therapeutics Insider Bought Shares Worth $2,001,800, According to a Recent SEC Filing	11-06	MT
Sarepta Therapeutics Insider Bought Shares Worth $3,940,500, According to a Recent SEC Filing	11-06	MT
Insider Buy: Sarepta Therapeutics	23-08-15	MT
Insider Buy: Sarepta Therapeutics	23-08-14	MT
Insider Buy: Sarepta Therapeutics	23-08-11	MT
Insider Sell: Sarepta Therapeutics	23-08-09	MT
Sarepta Therapeutics, Inc. Announces Executive Changes	22-11-02	CI
Insider Buy: Sarepta Therapeutics	22-09-15	MT
Insider Buy: Sarepta Therapeutics	22-08-22	MT
Sarepta Therapeutics, Inc. Appoints Michael Chambers and Kathryn Boor to Its Board of Directors	22-06-02	CI
Editas Medicine Appoints Sarepta Therapeutics Executive Gilmore O'Neill as CEO	22-04-14	MT
Sarepta Therapeutics, Inc. Announces Not Stand for Re-Election of Mary Ann Gray as Board of Director	22-04-06	CI
Insider Buy: Sarepta Therapeutics	21-11-29	MT
Sarepta Therapeutics Names Louise Rodino-Klapac as Head of Research and Development	21-11-17	CI
Sarepta Therapeutics Appoints Stephen L. Mayo to Its Board of Directors	21-11-17	CI
Selecta Biosciences : Names Kevin Tan Finance Chief	21-09-20	MT
Selecta Biosciences : Hires Kevin Tan as CFO	21-09-20	MT
Passage Bio : Names New Finance, Medical Chiefs	21-07-19	MT

No results for this search